Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antifolates in clinical development

C H Takimoto1, C J Allegra

  • 1Oncology Branch Bethesda Naval Hospital, Maryland, USA.

Oncology (Williston Park, N.Y.)
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Translation of anticancer efficacy from nonclinical models to the clinic.

CPT: pharmacometrics & systems pharmacology·2014
Same author

Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.

Cancer chemotherapy and pharmacology·2010
Same author

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.

Cancer chemotherapy and pharmacology·2009
Same author

N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

Bleeding diathesis in multiple myeloma.

Journal of hematotherapy & stem cell research·2001
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

New antifolate drugs are being developed to combat tumor cell resistance to methotrexate. These novel compounds, including trimetrexate and edatrexate, offer potential new anticancer therapies by targeting key enzymes and pathways.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Methotrexate resistance in tumor cells presents a significant challenge in cancer therapy.
  • Mechanisms of resistance include altered drug transport, metabolism, and target enzyme mutations.

Purpose of the Study:

  • To review novel antifolate drugs developed to overcome methotrexate resistance.
  • To profile their mechanisms of action, pharmacokinetics, and clinical efficacy.

Main Methods:

  • Literature review of antifolate drug development and clinical trials.
  • Analysis of drug mechanisms, including target enzyme interactions and resistance circumvention.

Main Results:

  • Several promising antifolate agents (trimetrexate, edatrexate, piritrexim, Tomudex, lometrexol) are in clinical testing.

Related Experiment Videos

  • These drugs exhibit diverse strategies to overcome known resistance pathways.

    • Conclusions:

    • New antifolates demonstrate potential as effective anticancer agents against resistant tumors.
    • Further clinical evaluation is warranted to establish their therapeutic roles.